LMWH bemiparin and ULMWH RO-14 reduce the endothelial angiogenic features elicited by leukemia, lung cancer, or breast cancer cells.
Low-molecular-weight heparins (LMWH) are anticoagulant drugs that also possess antitumor properties. We evaluated whether "second generation" LMWH bemiparin and the Ultra-Low-MWH (ULMWH) RO-14 are able to inhibit in vitro the angiogenic response of microvascular endothelium stimulated by tumor-cell-conditioned media (TCM) from human leukemia, lung cancer, and breast cancer cells. Bemiparin and RO-14 dose dependently inhibited the increase of capillary-like tube formation (Matrigel-based assay) and endothelial migration (wound-healing assay) induced by TCM. Both drugs also inhibited angiogenic response elicited by purified VEGF and FGF-2. These findings support a possible role of these molecules as adjuvant drugs in cancer treatment.
Division of Immunohematology and Transfusion Medicine, Department of Oncology-Hematology, Ospedali Riuniti di Bergamo, Bergamo, Italy.
Alfonso
A
Vignoli
Marina
M
Marchetti
Laura
L
Russo
Elena
E
Cantalino
Erika
E
Diani
Gaia
G
Bonacina
Anna
A
Falanga
D020533:Angiogenesis Inhibitors / Q000494:pharmacology*; D001943:Breast Neoplasms / Q000098:blood supply* / Q000188:drug therapy; D045744:Cell Line, Tumor; D042783:Endothelial Cells / Q000187:drug effects*; D005260:Female; D016222:Fibroblast Growth Factor 2 / Q000502:physiology; D006495:Heparin, Low-Molecular-Weight / Q000494:pharmacology*; D006801:Humans; D007938:Leukemia / Q000188:drug therapy / Q000503:physiopathology*; D008175:Lung Neoplasms / Q000098:blood supply* / Q000188:drug therapy; D008875:Middle Aged; D009389:Neovascularization, Pathologic / Q000188:drug therapy*; D042461:Vascular Endothelial Growth Factor A / Q000502:physiology; D014945:Wound Healing
D020533:Angiogenesis Inhibitors; D006495:Heparin, Low-Molecular-Weight; D042461:Vascular Endothelial Growth Factor A; D016222:Fibroblast Growth Factor 2; C411345:bemiparin